Accuray Incorporated (ARAY) has a MoatMap StockRank of 14/100 based on Quality (32/100), Value (54/100), and Momentum (13/100) factor scores. The current signal is STRONG SELL. Accuray manufactures radiation oncology systems. It operates in a highly competitive market with low margins, high capital intensity, and a weak track record of value creation, failing our quality screens.
Accuray Incorporated is a global radiation oncology company that designs, manufactures, and sells advanced radiotherapy systems, including the CyberKnife and TomoTherapy platforms. These systems deliver highly precise, personalized treatments for cancer patients while minimizing damage to surrounding healthy tissue. Accuray's competitive moat is established through its proprietary motion-tracking and synchronization technologies, which allow for real-time adaptation during treatment delivery.
| Price | $0.33 |
| Market Cap | $53M |
| P/E (Forward) | -1.52 |
| Price/Book | 1.04 |
| Return on Equity | -101.1% |
| Return on Invested Capital | 5.1% |
| Debt/Equity | 437.33 |
| Gross Margin | 26.9% |
| Operating Margin | -2.4% |
| Revenue Growth | -7.4% |
| Free Cash Flow | $-11M |
Accuray Incorporated operates in the Medical Devices industry, part of the Healthcare sector (United States).